Coherus BioSciences (CHRS)
(Delayed Data from NSDQ)
$1.39 USD
+0.07 (5.30%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $1.38 -0.01 (-0.72%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.39 USD
+0.07 (5.30%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $1.38 -0.01 (-0.72%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Zacks News
Trevena's NDA for Pain Drug Oliceridine Gets FDA Acceptance
by Zacks Equity Research
FDA accepts Trevena's (TRVN) NDA for opioid analgesic, oliceridine, re-submitted last month. A decision is expected in August.
5 Stocks Trading Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Coherus (CHRS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
We expect Coherus BioSciences (CHRS) to provide updates on its pipeline when it releases fourth-quarter 2019 results.
Coherus BioSciences (CHRS) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Coherus BioSciences (CHRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Has Coherus BioSciences (CHRS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (CHRS) Outperforming Other Medical Stocks This Year?
Arena's (ARNA) Heart Failure Candidate Gets Fast Track Status
by Zacks Equity Research
The FDA grants fast track status to Arena's (ARNA) early-stage candidate, APD418, for the treatment of decompensated heart failure.
Amarin Posts '19 Preliminary Results, Gives 2020 Expense View
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales witness strong growth. The trend is anticipated to continue in 2020. However, the operating expense guidance for 2020 was higher than expected, which probably pulled the stock down.
Is Coherus BioSciences (CHRS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CHRS) Outperforming Other Medical Stocks This Year?
Protagonist (PTGX) Starts Study on PTG-300 for Blood Disorder
by Zacks Equity Research
Protagonist's (PTGX) phase II study on PTG-300 will evaluate it as a potential treatment for hereditary hemochromatosis, a rare blood disorder, caused due to accumulation of iron.
Pulmatrix Surges on License Agreement With Johnson & Johnson
by Zacks Equity Research
Pulmatrix (PULM) inks an agreement with an entity of J&J, granting it the license to develop a portfolio of narrow spectrum kinase inhibitors for lung cancer interception.
Arena (ARNA) Expands Strategic Deal With Beacon Discovery
by Zacks Equity Research
Arena (ARNA) enters into multi-year strategic partnership with Beacon Discovery to discover and develop therapies targeting multiple immune and inflammatory indications.
Flexion's (FLXN) Stock Up on FDA Approval for Zilretta sNDA
by Zacks Equity Research
Flexion's (FLXN) sNDA for osteoarthritis drug, Zilretta, seeking removal of confusing limitation of use label, gets FDA approval.
Has Coherus BioSciences (CHRS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (CHRS) Outperforming Other Medical Stocks This Year?
5 Biotech Stocks Set for Continued Rally in 2020
by Zacks Equity Research
The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.
Top Ranked Momentum Stocks to Buy for December 3rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 3rd
Top Ranked Momentum Stocks to Buy for November 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 26th
Alkermes to Acquire Rodin Therapeutics, Boost CNS Pipeline
by Zacks Equity Research
Alkermes (ALKS) will acquire Rodin Therapeutics for an upfront cash payment of $100 million and up to $850 million in milestone payments.
The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
4 Biotech Stocks That Could Keep Beating Wall Street
by Zacks Equity Research
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
Coherus BioSciences (CHRS) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 75.00% and 19.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Investors Can Find Strong Stocks with our First Profit Screen
by Benjamin Rains
Today, we are utilizing our 'First Profit' stock screen to help investors find strong stocks. The idea is to search for companies that just reported their first quarterly profit within the last year...
Coherus BioSciences (CHRS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Coherus BioSciences (CHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Investors Can Find Big Returns with this First Profit Screen
by Benjamin Rains
We are taking a look at our 'First Profit' stock screen today. The idea is to search for companies that just reported their first quarterly profit within the last year because these firms could prove to be big winners for investors...
Coherus BioSciences (CHRS) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 500.00% and 2.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Top Ranked Momentum Stocks to Buy for July 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 12th